GLP-1 agonists and metabolic peptides for weight management - semaglutide, tirzepatide, AOD-9604 with protocols.
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Marketed as Ozempic/Wegovy. Achieves 15-17% body weight loss in clinical trials.
Dose: 0.25 mg → titrate up to 2.4 mg | Route: Subcutaneous injection
A dual GIP and GLP-1 receptor agonist approved as Mounjaro/Zepbound. Achieves up to 22.5% body weight loss, the highest of approved therapies.
Dose: 2.5 mg → titrate up to 15 mg | Route: Subcutaneous injection
A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis. Originally developed as an anti-obesity drug with no effect on IGF-1 or blood gluc
Dose: 300 mcg | Route: Subcutaneous injection
A synthetic GHRH analog FDA-approved for HIV-associated lipodystrophy. Particularly effective at reducing visceral adipose tissue with emerging cognitive benefits.
Dose: 2 mg | Route: Subcutaneous injection
CJC-1295 conjugated with DAC that binds albumin, extending half-life to ~8 days. Creates sustained GH elevation rather than pulsatile release.
Dose: 2 mg | Route: Subcutaneous
Read full CJC-1295 DAC guide →
A novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 shows unprecedented 24% body weight loss at 48 weeks.
Dose: 1-2 mg → titrate up to 12 mg | Route: Subcutaneous injection
A triple monoamine reuptake inhibitor that blocks norepinephrine, serotonin, and dopamine reuptake, producing significant appetite suppression and increased metabolic rate.
Dose: 0.25-0.5 mg | Route: Oral
A fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) targeting complementary appetite pathways for enhanced weight loss.
Dose: Cagrilintide 2.4mg + Semaglutide 2.4mg | Route: Subcutaneous
A dual agonist of GLP-1 and glucagon receptors being developed for obesity and MASH. Glucagon component provides added metabolic benefits through increased energy expenditure.
Dose: 0.6-6.0 mg | Route: Subcutaneous
A first-in-class oral non-peptide GLP-1 receptor agonist with high oral bioavailability, potentially democratizing GLP-1 therapy without injections.
Dose: 12-45 mg | Route: Oral
Read full Orforglipron guide →
The first GLP-1 receptor agonist approved for chronic weight management (as Saxenda at 3.0mg). A 97% homolog of native GLP-1 with fatty acid modification for once-daily dosing.
Dose: 0.6-3.0 mg | Route: Subcutaneous
A dual GLP-1/glucagon receptor agonist with promising weight loss results comparable to tirzepatide, including additional hepatic fat reduction.
Dose: 3-9 mg | Route: Subcutaneous